
































































Comment on Kronenfeld et al. Clinical Outcomes for Primary
and Radiation-Associated Angiosarcoma of the Breast with
Multimodal Treatment: Long-Term Survival Is Achievable.
Cancers 2021, 13, 3814
Markus Notter 1,2,* , Emanuel Stutz 2,3, Andreas R. Thomsen 4,5 , Attila Kollár 6,7 and Peter Vaupel 4,5


Citation: Notter, M.; Stutz, E.;
Thomsen, A.R.; Kollár, A.; Vaupel, P.
Comment on Kronenfeld et al.
Clinical Outcomes for Primary and
Radiation-Associated Angiosarcoma
of the Breast with Multimodal
Treatment: Long-Term Survival Is
Achievable. Cancers 2021, 13, 3814.
Cancers 2021, 13, 5707. https://
doi.org/10.3390/10.3390/
cancers13225707
Academic Editors: Robert J. Canter
and Steven W. Thorpe
Received: 24 August 2021
Accepted: 10 November 2021
Published: 15 November 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Radiation Oncology, Lindenhofspital Bern, 3012 Bern, Switzerland
2 Member of the Swiss Hyperthermia Network, 5000 Aarau, Switzerland; Emanuel.stutz@insel.ch
3 Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern,
3010 Bern, Switzerland
4 Department of Radiation Oncology, University Medical Center, University of Freiburg,
79106 Freiburg, Germany; andreas.thomsen@uniklinik-freiburg.de (A.R.T.); vaupel@uni-mainz.de (P.V.)
5 German Cancer Consortium (DKTK), Partner Site Freiburg and German Cancer Research Center (DKFZ),
69120 Heidelberg, Germany
6 Department of Medical Oncology, Inselspital Bern University Hospital, University of Bern,
3010 Bern, Switzerland; attila.kollar@insel.ch
7 Sarcoma Center, Inselspital Bern University Hospital, University of Bern, 3010 Bern, Switzerland
* Correspondence: markus.notter@lindenhofgruppe.ch
On 2 July 2021, Kronenfeld et al. [1] published an excellent analysis of the clini-
cal outcomes of primary angiosarcomas of the breast (PAS) and radiation-associated an-
giosarcomas of the breast (RAASB) treated with multimodality therapy in the last decade
(2010–2020). They concluded, that a multimodal treatment approach that included neoad-
juvant chemotherapy (NAC), radiation therapy (RT) in selected patients, surgery (S), and
adjuvant chemotherapy (AC) may result in improved outcomes, including prolonged
survival. Despite the small sample size, they demonstrated that NAC, especially when
associated with a pathologic complete response, may contribute to these substantial results.
We thoroughly support their conclusion that in addition to dedicated surgical procedures
as the primary means of treatment, further pre- or postoperative treatment is urgently
needed. However, the recommendation for focusing predominantly on systemic treatments
is too limited.
PAS and RAASB should be considered as different tumor entities with regard to
treatment strategies largely due to the restricted treatment options for RAASB. PASs
occur mostly in younger women and have a higher potential of distant metastasis. As
RAASB patients have received prior breast cancer treatment with adjuvant radiation. With
respect to PAS, aggressive NAC, postoperative AC, or full dosed postoperative RT could be
considered, especially in cases with insufficient margins. This is less the case with radiation-
associated angiosarcomas (RAAS). Previously irradiated sites do not always allow for an
adequate re-irradiation (re-RT) dose. Surgical procedures should solve reconstructive
challenges and may be hampered by prolonged wound healing among other complications.
The effectiveness of systemic treatments can also be affected as a result of reduced perfusion
in heavily pre-irradiated tissue. In addition, the incidence of local recurrences in both tumor
types is rather high as reported by several authors [2]. Therefore, additional adjuvant local
treatment as a therapeutic option must be evaluated as well.
In a similar timeframe as the aforementioned analysis (2011–2021), we have focused on
new treatment strategies for RAASB specifically for recurrent tumors, which have the worst
prognosis. Based on findings of earlier studies using hyperthermia and re-irradiation in
locally recurrent breast cancer, we found that the combination of both modalities allowed
for a reduction of the total re-irradiation dose to just 20 Gy using a hypofractionated
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schedule of 5 × 4 Gy once per week [3]. To our knowledge, this is the lowest total re-
irradiation dose applied so far in a protocol that aims for effective tumor control. Contact-
free water filtered infrared-A superficial hyperthermia allows for greater coverage of
large-sized lesions, and can reduce the risk of thermal skin damage to a minimum [4]. In
contrast to most reported protocols, our protocol involves the utilization of hyperthermia
prior to re-RT. The low toxicity of this protocol even allows for repeat re-RT using the same
dosage and schedule. This is crucial in the management of RAASB, which is often locally
recurring despite the usage of large treatment fields and sufficient margins.
Coincidentally, our results [5] were published 4 days later after the study carried outby
Kronenfeld et al. [1]. Both analyses obviously represented different RAASB situations in
completely different tumor stages. The Kronenfeld cohort contained patients treated at
first diagnosis in a localized stage as the clinical tumor size varied from 2 to 7 cm (median
2.8 cm). Therefore, all patients were resectable and in 100% a R0 resection was possible.
In contrast to their patients, 8 out of 10 of our patients presented with locally recurrent
disease after a first resection of the RAASB, most of them even locally very advanced
with a tumor extension classified as III (still limited to the ipsilateral chest wall) or IV (far
extended beyond ipsilateral chest wall, see Figure 1 in [5]). In such situations standard
treatment recommendations are clearly missed but it is obvious, that an additional local
treatment approach is needed. The presented treatment schedule is a promising option to
further reduce the radiation dose recommended so far. This could reduce side effects in
patients without compromising local control. In addition, this treatment could be an option
for elderly patients with reduced physical condition, as they may not be able to tolerate
extended radical surgery or aggressive systemic therapy. However, due to total number of
cases in both publications [1,5] further research is needed.
Angiosarcomas of the breast, whether it be PAS or RAAS, remain a very challenging
disease to treat. Communications of different treatment approaches, e.g., extended surgical
procedures, NAC or AC, adjuvant RT, or re-RT with/without hyperthermia reflect the
whole spectrum of attempts to improve local and general tumor control. A combination
of all four treatment modalities may be the key solution to this disease, with adaptions to
each respective case. Moderate, regional hyperthermia is not only a radiosensitizer but
also a chemosensitizer. In a randomized phase III trial comparing regional hyperthermia
combined with chemotherapy to chemotherapy alone, the addition of hyperthermia signif-
icantly improved not only local tumor control but also overall survival in patients with
high-risk soft tissue sarcomas [6]. One of the largest multicenter studies retrospectively
analyzed the outcome of angiosarcoma patients concluding, that multimodal treatment
may be beneficial for angiosarcomas [7], but the role of NAC should be further explored.
To conclude: prospective, multi-institutional studies are clearly needed. How to
proceed from here? A first step could be to establish an international-wide patterns of care
study with participation of all interested centers. If this works, and a consensus is found,
a prospective evaluation of different treatment concepts including systemic treatments
and local therapies can be started. The potential of additional loco-regional hyperthermia
as a radio-, chemo- and immune-sensitizer could then be integrated into these curative
strategies. We are interested in remarks and suggestions from the scientific community
about further strategies to improve outcomes and the level of treatment recommendations.
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